http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201491934-A1

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
filingDate 2013-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2015-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EA-201491934-A1
titleOfInvention GLUCAGON-LIKE PEPTIDE-2 ANALOGES (GLP-2)
abstract GLP-2 analogues are described which contain one or more substitutions compared to h [Gly2] GLP-2 and which may have the property of altered GLP-1 activity, and their use in medicine. These analogs are particularly useful in the prevention, treatment or alleviation of the adverse effects of diabetes associated with the gastrointestinal tract.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2795594-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11660328-B2
priorityDate 2012-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID373686
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID280802
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID14526
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID396196
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2641
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3772480
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3771769
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID494052
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426361441
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID397595
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71300624
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3772194

Total number of triples: 47.